Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.89% | 25.84% | 16.29% | 28.05% | 24.04% |
| Total Depreciation and Amortization | 12.19% | -16.48% | -17.17% | -9.55% | -11.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.26% | -21.99% | -16.39% | -20.01% | 0.60% |
| Change in Net Operating Assets | 808.72% | -261.32% | -255.61% | 7,880.50% | 189.85% |
| Cash from Operations | 375.93% | -5.44% | -2.27% | 220.39% | 58.41% |
| Capital Expenditure | -- | -- | -- | 93.35% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 93.35% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 99.69% | 98.14% | -98.70% |
| Issuance of Common Stock | 12.16% | 15,088.89% | -50.00% | 14,231.43% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 406.50% | 601.96% | 99.87% | 2,120.46% | 156.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 453.88% | 60.42% | 12.31% | 323.55% | 64.78% |